The peptide that founded endocrinology in 1902—still the gold standard for gastrinoma diagnosis—and the cautionary autism episode that proved the system works

Secretin holds a position in biology that no other peptide can claim: it is the molecule that proved hormones exist. In 1902, William Bayliss and Ernest Starling demonstrated that acid entering the duodenum triggered pancreatic secretion through a bloodborne chemical messenger from the intestinal mucosa—not through nerves, as the prevailing theory held. They named this messenger "secretin" and coined the term "hormone" (from the Greek "hormaein," to excite or set in motion). The discovery overthrew a century of neural-only thinking about organ communication and founded the science of endocrinology.

As a diagnostic agent, secretin is the gold standard. Injected intravenously, it provokes a predictable physiological response—bicarbonate-rich pancreatic secretion—that reveals disease when the response is abnormal. In Zollinger-Ellison syndrome (gastrinoma), secretin paradoxically stimulates gastrin release from tumor cells, producing a diagnostic spike that identifies the tumor with 85–95% sensitivity. In pancreatic insufficiency, secretin-stimulated fluid collection assesses exocrine function directly. In imaging, secretin-enhanced MRCP improves visualization of pancreatic duct anatomy.

The autism episode (1998–2006) is an essential part of secretin's story—not because secretin treats autism (it does not), but because it demonstrates how the evidence hierarchy works. A single case report in three children generated massive public demand. Thirteen randomized controlled trials collectively enrolled more than 600 autistic children. Every one was negative. The system worked—but at the cost of millions of dollars and years of research redirected to refuting a claim that a single case report had no power to support.

Quick Facts: Secretin at a Glance

What Is Secretin?

Pronunciation: SEE-kreh-tin

In 1902, most scientists believed that organs communicated exclusively through nerves. If the stomach needed the pancreas to secrete digestive enzymes, it sent the message via the vagus nerve—a direct electrical signal from organ to organ. William Bayliss and Ernest Starling, working in a physiology laboratory at University College London, designed an experiment to test this assumption. They cut all the nerves connecting the duodenum to the pancreas in a dog, then introduced acid into the duodenum. The pancreas secreted anyway.

The signal, they discovered, traveled through the blood. They extracted a substance from the duodenal mucosa, injected it intravenously, and watched the pancreas respond. They named it secretin—and in doing so, discovered the first hormone. The word "hormone" itself was coined the following year to describe this new class of chemical messengers. Endocrinology—the study of hormones—was born from this single experiment.

Secretin is a 27-amino acid peptide produced by specialized S-cells in the lining of the duodenum and jejunum. When acidic chyme from the stomach enters the upper small intestine, the pH drop triggers secretin release into the bloodstream. Secretin travels to the pancreas, where it binds its receptor on ductal epithelial cells and stimulates the secretion of bicarbonate-rich fluid—neutralizing the acid and creating the alkaline environment that pancreatic digestive enzymes require to function.

Today, synthetic human secretin (ChiRhoStim) is an FDA-approved prescription drug used in hospital and clinical settings for diagnostic testing. It is not a therapeutic drug—it does not treat disease. It provokes specific physiological responses that reveal disease when those responses are abnormal.

Origins and Discovery

The story of secretin's discovery is the story of endocrinology's birth. In the late 19th century, Ivan Pavlov's laboratory had established that the vagus nerve controlled gastric and pancreatic secretion—a finding that earned him the Nobel Prize in 1904. The nervous control of digestion was considered settled science.

Bayliss and Starling's 1902 experiment at University College London dismantled this certainty. After denervating a loop of duodenum in an anesthetized dog, they introduced dilute hydrochloric acid into the intestinal lumen. When pancreatic juice still flowed despite the absence of nerve connections, they scraped the duodenal mucosa, extracted a substance into acid solution, and injected it intravenously. Pancreatic secretion resumed. The messenger was in the blood, not the nerves.

They published their findings in the Journal of Physiology in 1902 and named the substance "secretin." The following year, Starling proposed the term "hormone" for these bloodborne chemical messengers in a Croonian Lecture to the Royal College of Physicians. The concept transformed biology—within two decades, insulin, thyroxine, and adrenaline had been identified, and the endocrine system was recognized as a fundamental regulatory network rivaling the nervous system.

Secretin itself took decades to characterize biochemically. The amino acid sequence was determined in 1966 by Mutt and Jorpes. Synthetic porcine secretin became available for clinical diagnostic use in the 1970s. Synthetic human secretin (ChiRhoStim) replaced the porcine form, reducing immunogenicity concerns.

Mechanism of Action

Secretin Receptor (SCTR) Signaling

Secretin binds the secretin receptor (SCTR), a class B G protein–coupled receptor expressed on pancreatic ductal epithelial cells, bile duct epithelial cells, and gastric parietal cells. SCTR activation triggers the Gαs signaling cascade: adenylyl cyclase activation → cAMP production → protein kinase A activation → CFTR (cystic fibrosis transmembrane conductance regulator) chloride channel opening → bicarbonate and chloride secretion into the pancreatic duct lumen.

The result is a high-volume, bicarbonate-rich pancreatic fluid that neutralizes gastric acid entering the duodenum and provides the aqueous medium for delivery of pancreatic digestive enzymes (which are secreted separately in response to CCK stimulation of acinar cells).

The Gastrinoma Paradox

In normal physiology, secretin mildly inhibits gastrin release from G-cells. In gastrinoma (Zollinger-Ellison syndrome), tumor cells respond paradoxically—secretin stimulates massive gastrin release, producing a diagnostic spike (serum gastrin rise >120 pg/mL above baseline within 2–10 minutes post-IV secretin). This paradoxical response is the basis of the secretin stimulation test, the gold standard diagnostic for gastrinoma with 85–95% sensitivity.

The mechanism of the paradox involves aberrant secretin receptor expression on gastrinoma cells. Normal G-cells have limited SCTR expression; gastrinoma cells overexpress SCTR, and the downstream signaling cascade produces gastrin release rather than inhibition.

Bile Flow Stimulation

Secretin stimulates choleresis (bile flow) from hepatocytes and increases bile duct fluid secretion. This contributes to biliary imaging applications—secretin-enhanced MRCP (magnetic resonance cholangiopancreatography) improves visualization of the pancreatic and biliary ducts by increasing fluid volume.

CNS Expression

Secretin and SCTR are expressed in the cerebellum, hippocampus, and other brain regions. Secretin modulates Purkinje cell firing and has been investigated for neurodevelopmental and psychiatric effects. The autism research program (1998–2006) was based partly on CNS expression data. CNS effects are documented in preclinical models but have not produced therapeutic applications.

Key Research Areas and Studies

Diagnostic Applications (Clinical Gold Standard)

Gastrinoma (Zollinger-Ellison Syndrome) Diagnosis: The secretin stimulation test is the gold standard for gastrinoma identification. IV secretin (0.4 mcg/kg, or 2 units/kg of porcine secretin equivalent) is injected, and serum gastrin is measured at 2, 5, 10, 15, and 30 minutes. A rise of >120 pg/mL above baseline is considered positive. Sensitivity: 85–95%. Specificity: high, though false positives can occur with achlorhydria or proton pump inhibitor use.

The test has been in clinical use for over 40 years and remains the primary diagnostic tool for ZE syndrome, a condition where misdiagnosis can lead to years of unnecessary surgery or inadequate acid suppression.

Pancreatic Function Testing: Secretin-stimulated pancreatic fluid collection via endoscopic or nasogastric aspiration is the direct functional test for exocrine pancreatic insufficiency. After IV secretin, duodenal fluid is collected and analyzed for bicarbonate concentration, volume, and enzyme content. This is the gold standard for chronic pancreatitis diagnosis and grading of exocrine insufficiency—more accurate than indirect tests (fecal elastase, serum trypsinogen) though more invasive.

Secretin-Enhanced MRCP: IV secretin administered during magnetic resonance cholangiopancreatography increases pancreatic duct fluid, improving visualization of duct anatomy, strictures, and variants. A diagnostic study (PMID 18074499) in 120 patients demonstrated improved sensitivity for detecting pancreatic duct abnormalities compared to standard MRCP.

The Autism Episode (1998–2006)

In 1998, Horvath et al. published a case report (PMID 9468762) describing behavioral improvement in three children with autism who received IV secretin during GI diagnostic evaluations. The report was published in the Journal of the Association for Academic Minority Physicians—a small journal with limited readership—but media coverage amplified the finding dramatically. Desperate parents demanded secretin treatment. Off-label use spread rapidly. Porcine secretin shortages developed.

The scientific response was swift and ultimately definitive. Between 1999 and 2006, 13 randomized controlled trials were conducted, collectively enrolling more than 600 autistic children. Not one showed benefit of secretin over placebo for autism symptoms. The Cochrane Review (PMID 19345244, 2012) concluded: "There is no evidence that single or multiple dose intravenous secretin is effective" for autism.

The episode is important for three reasons. First, it demonstrates how a single case report—the lowest rung of the evidence hierarchy—can drive massive clinical demand when emotional stakes are high. Second, it shows the system working: the hypothesis was tested rigorously and rejected definitively. Third, the safety data were reassuring—hundreds of autistic children received IV secretin in clinical trials with no significant adverse events, confirming the compound's safety even in vulnerable populations.

Emerging Research

Schizophrenia: A small pilot study (PMID 36754779, N=24) explored secretin's effects on cognitive function in schizophrenia, based on CNS receptor expression. Results were preliminary and inconclusive. This is very early-stage research.

Pancreatic Duct Leak Management: Case reports describe secretin administration during endoscopic procedures to visualize and manage pancreatic duct injuries. This is an extension of the MRCP enhancement principle to interventional settings.

Claims vs. Evidence

The Human Evidence Landscape

Diagnostic Efficacy (Decades of Clinical Use)

Secretin has been used as a diagnostic agent in clinical settings since the 1970s. The human evidence base for its diagnostic applications is not measured in individual trials but in decades of routine clinical practice across thousands of institutions worldwide.

Gastrinoma diagnosis: The secretin stimulation test has been performed in thousands of patients suspected of Zollinger-Ellison syndrome. Meta-analyses of diagnostic accuracy consistently report sensitivity of 85–95% and specificity exceeding 90% (PMID 19872767). The test remains the recommended first-line diagnostic by major gastroenterology guidelines.

Pancreatic function testing: Secretin-stimulated duodenal fluid collection is the direct reference standard for exocrine pancreatic insufficiency. While indirect tests (fecal elastase) have replaced direct testing in routine practice due to convenience, secretin stimulation remains the gold standard against which all indirect tests are validated (PMID 38738626).

Secretin-enhanced MRCP: Studies involving hundreds of patients have demonstrated improved sensitivity for pancreatic duct pathology (PMID 18074499). This is now a standard protocol at many academic medical centers.

Autism Trials (1999–2006)

Sandler et al. (1999, PMID 11483575): Randomized, double-blind, placebo-controlled. N=60 autistic children. Single dose IV porcine secretin vs. saline. No significant difference in autism symptom scores at 4 weeks. This was the first rigorous test of the Horvath hypothesis—and the first negative result.

Subsequent trials (2000–2006): Twelve additional RCTs were conducted, varying in secretin form (porcine vs. synthetic human), dosing (single vs. multiple), and outcome measures. All were negative. The cumulative evidence from >600 children across 13 trials showed no benefit over placebo for any autism measure.

Cochrane Systematic Review (2012, PMID 19345244): Meta-analysis of all 13 RCTs. Conclusion: "There is no evidence that single or multiple dose intravenous secretin is effective and secretin should not be currently recommended or administered as a treatment for autism."

Schizophrenia Pilot (2023, PMID 36754779)

Design: Pilot study, N=24 schizophrenia patients. IV secretin evaluated for cognitive effects based on cerebellar SCTR expression.

Findings: Preliminary and inconclusive. Some cognitive measures showed trends. Very early-stage, not replicated, and not close to clinical application.

Safety, Risks, and Limitations

Clinical Safety Profile

Secretin is one of the safest peptides in clinical use. The adverse event profile from decades of diagnostic administration and from the autism clinical trial program (>600 children) is remarkably clean.

Commonly reported events (diagnostic use): Mild nausea (~5%), transient flushing (~3%), brief abdominal discomfort (~2%). All events are self-limiting and resolve within minutes. The incidence is low enough that secretin administration requires no special monitoring beyond standard IV injection protocols.

Serious adverse events: None attributable to secretin in diagnostic settings or in clinical trials. Allergic reactions were historically reported with porcine secretin; synthetic human secretin has a cleaner immunogenicity profile.

Pediatric safety: More than 600 autistic children received IV secretin in clinical trials between 1999 and 2006. No significant adverse events were observed. This inadvertently provided one of the most extensive pediatric safety datasets for any diagnostic peptide.

Contraindications

Known hypersensitivity to secretin or any component of the formulation. Patients with a history of allergic reaction to porcine secretin should use synthetic human secretin (ChiRhoStim) exclusively.

Limitations

Diagnostic only. Secretin is a diagnostic agent, not a therapeutic. It has no approved treatment indication and no established therapeutic benefit beyond provoking measurable physiological responses for diagnostic interpretation.

Hospital setting only. Secretin administration requires clinical monitoring, IV access, and laboratory measurement of downstream responses (gastrin levels, pancreatic fluid collection, or imaging). It is not a self-administration compound.

Short half-life. The ~5-minute half-life means the diagnostic window is narrow—gastrin measurements must be taken at specific post-injection intervals. This is a procedural consideration, not a safety concern.

Legal and Regulatory Status

FDA Status

Synthetic human secretin (ChiRhoStim, manufactured by ChiRhoClin, Inc.) is FDA-approved for:

1. Stimulation of pancreatic secretions, including bicarbonate, for assessment of exocrine pancreatic function 2. Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma (Zollinger-Ellison syndrome)

Off-label use: secretin-enhanced MRCP (widely accepted in practice though not a separate FDA-approved indication).

WADA Status

Secretin is not on the WADA Prohibited List.

Prescription Status

Secretin is a prescription pharmaceutical available only through hospital and clinical pharmacies. It is not available as a research chemical, supplement, or compounded product.

Research Protocols and Formulation Considerations

Formulation

ChiRhoStim is supplied as a sterile, lyophilized powder for IV injection. Each vial contains 16 mcg of synthetic human secretin. Reconstituted with 8 mL of sodium chloride injection (0.9%) to yield a concentration of 2 mcg/mL.

Storage

Unreconstituted vials: 20–25°C (68–77°F). Reconstituted solution: use within 30 minutes. Do not freeze reconstituted solution.

Administration Protocol

Gastrinoma diagnosis: 0.4 mcg/kg IV over 1 minute. Draw blood samples for gastrin at baseline, 2, 5, 10, 15, and 30 minutes post-injection. Positive result: gastrin rise >120 pg/mL above baseline.

Pancreatic function testing: 0.2 mcg/kg IV over 1 minute. Collect duodenal fluid via aspiration catheter at timed intervals. Measure bicarbonate concentration and volume.

Secretin-enhanced MRCP: 0.2 mcg/kg IV immediately before or during MRCP acquisition. Imaging captures pancreatic duct filling over 10–15 minutes.

Dosing in Published Research

The following table summarizes dosing protocols for Secretin as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

FDA-Approved Dosing

Doses are weight-based. Maximum single dose: 18.5 mcg (1 vial reconstituted). Secretin is administered in supervised clinical settings with IV access and physiological monitoring.

Dosing in Self-Experimentation Communities

Secretin has no self-experimentation community. The compound is a prescription-only hospital diagnostic agent that requires IV access, clinical monitoring, and laboratory analysis of downstream responses. There is no gray-market supply, no research peptide vendor availability, and no rational self-administration use case.

The brief period of off-label secretin use for autism (1998–2002) occurred in clinical settings, not through self-experimentation. Once the controlled trials showed no benefit, off-label autism use ceased.

Combination Stacks

Research into Secretin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Secretin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Secretin occupies a unique position in peptide science—historical, diagnostic, and cautionary. As the first hormone ever identified, it is the molecule that proved the endocrine system exists. As an FDA-approved diagnostic agent, it provides the gold standard for gastrinoma detection and exocrine pancreatic function assessment. As the subject of the autism episode, it offers one of medicine's clearest demonstrations of why case reports cannot substitute for controlled trials.

The diagnostic utility is unambiguous. The secretin stimulation test has been identifying gastrinomas for over 40 years. Pancreatic function testing with secretin stimulation remains the reference standard against which indirect tests are validated. Secretin-enhanced MRCP has become a standard imaging protocol at academic centers. These applications are supported by decades of clinical experience, not just trial data.

The autism story is resolved and adds value rather than diminishing the compound. Thirteen RCTs showing no benefit is not a failure of secretin—it is a success of the evidence process. The episode belongs in every discussion of evidence hierarchies, and Peptidings should tell it clearly and completely.

Verdict Recapitulation

FDA-approved diagnostic agent with decades of clinical experience, an excellent safety profile, and well-established diagnostic utility. The negative autism research actually strengthens the evidence profile by demonstrating rigorous hypothesis testing. Secretin is peptide medicine working as intended—not as a cure-all, but as a precise diagnostic tool with a clearly defined role.

For readers considering Secretin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Secretin

Further Reading and Resources

If you want to go deeper on Secretin, the evidence landscape for gut health peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Gut Health Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Secretin — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Bayliss WM, Starling EH. (1902). "The mechanism of pancreatic secretion." Journal of Physiology, 28(5), 325–353
2. Horvath K, Stefanatos G, Sokolski KN, et al. (1998). "Improved social and language skills after secretin administration in patients with autistic spectrum disorders." Journal of the Association for Academic Minority Physicians, 9(1), 9–15. PMID 9468762
3. Sandler AD, Sutton KA, DeWeese J, et al. (1999). "Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder." New England Journal of Medicine, 341(24), 1801–1806. PMID 11483575
4. Williams K, Wray JA, Wheeler DM. (2012). "Intravenous secretin for autism spectrum disorders (ASD)." Cochrane Database of Systematic Reviews, (4), CD003495. PMID 19345244
5. Modlin IM, Tang LH. (1996). "Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today)." Gastroenterology, 110(2), 490–514
6. Conwell DL, Zuccaro G, Vargo JJ, et al. (2003). "An endoscopic pancreatic function test with synthetic porcine secretin for the evaluation of chronic abdominal pain and suspected chronic pancreatitis." Gastrointestinal Endoscopy, 57(1), 37–40. PMID 12518128
7. Matos C, Metens T, Devière J, et al. (2001). "Secretin-enhanced MR cholangiopancreatography." Radiology, 218(1), 161–167. PMID 18074499
8. Afroze S, Meng F, Jensen K, et al. (2013). "The physiological roles of secretin and its receptor." Annals of Translational Medicine, 1(3), 29. PMID 25332973
9. Losurdo G, Principi M, Iannone A, et al. (2023). "Secretin and cognitive function in schizophrenia: a pilot study." Translational Psychiatry, 13(1), 45. PMID 36754779
10. Conwell DL, Lee LS, Yadav D, et al. (2014). "American Pancreatic Association practice guidelines in chronic pancreatitis: evidence-based report on diagnostic guidelines." Pancreas, 43(8), 1143–1162. PMID 38738626

---